Explore

Trendline Trendline
Sanofi's Lunsekimig Shows Promise in Asthma and Rhinosinusitis, Falls Short in Eczema Trial

Sanofi's Lunsekimig Shows Promise in Asthma and Rhinosinusitis, Falls Short in Eczema Trial

Sanofi's Lunsekimig Shows Promise in Asthma and Rhinosinusitis, Falls Short in Eczema Trial
Trendline Trendline
Sanofi's Lunsekimig Shows Mixed Results in Phase 2 Trials for Respiratory and Skin Conditions

Sanofi's Lunsekimig Shows Mixed Results in Phase 2 Trials for Respiratory and Skin Conditions

Sanofi's Lunsekimig Shows Mixed Results in Phase 2 Trials for Respiratory and Skin Conditions
Trendline Trendline
Sanofi's Lunsekimig Shows Mixed Results in Phase 2 Trials for Respiratory and Dermatology Conditions

Sanofi's Lunsekimig Shows Mixed Results in Phase 2 Trials for Respiratory and Dermatology Conditions

Sanofi's Lunsekimig Shows Mixed Results in Phase 2 Trials for Respiratory and Dermatology Conditions
Trendline Trendline
FDA Reversals in Rare Disease Trials Highlight Challenges with External Controls

FDA Reversals in Rare Disease Trials Highlight Challenges with External Controls

FDA Reversals in Rare Disease Trials Highlight Challenges with External Controls
Trendline Trendline
API's Lean Derisking Strategy Aims to Streamline Drug Development

API's Lean Derisking Strategy Aims to Streamline Drug Development

API's Lean Derisking Strategy Aims to Streamline Drug Development
Trendline Trendline
Evommune to Explore MRGPRX2 Inhibition for Migraine Treatment

Evommune to Explore MRGPRX2 Inhibition for Migraine Treatment

Evommune to Explore MRGPRX2 Inhibition for Migraine Treatment
Trendline Trendline
Allucent Expands Leadership to Enhance Drug Development for Biopharma

Allucent Expands Leadership to Enhance Drug Development for Biopharma

Allucent Expands Leadership to Enhance Drug Development for Biopharma
Trendline Trendline
API's Strategic Approach to Drug Development Aims to Overcome 'Valley of Death'

API's Strategic Approach to Drug Development Aims to Overcome 'Valley of Death'

API's Strategic Approach to Drug Development Aims to Overcome 'Valley of Death'
Trendline Trendline
Amgen's New Tepezza Formulation Shows Promise in Phase 3 Trials

Amgen's New Tepezza Formulation Shows Promise in Phase 3 Trials

Amgen's New Tepezza Formulation Shows Promise in Phase 3 Trials
Trendline Trendline
Cingulate Inc. Advances ADHD Treatment Amid Regulatory Focus

Cingulate Inc. Advances ADHD Treatment Amid Regulatory Focus

Cingulate Inc. Advances ADHD Treatment Amid Regulatory Focus
Trendline Trendline
Gilead Sciences Acquires Tubulis in $5 Billion Deal to Expand Oncology Portfolio

Gilead Sciences Acquires Tubulis in $5 Billion Deal to Expand Oncology Portfolio

Gilead Sciences Acquires Tubulis in $5 Billion Deal to Expand Oncology Portfolio
Trendline Trendline
Amgen's New Tepezza Formulation Aims to Boost Sales Amidst Market Challenges

Amgen's New Tepezza Formulation Aims to Boost Sales Amidst Market Challenges

Amgen's New Tepezza Formulation Aims to Boost Sales Amidst Market Challenges